Santhera Pharmaceuticals announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE (vamorolone) in India, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.
Leia mais: O que é Agamree (vamorolona)? Para que é usado o Agamree?
The agreement between Santhera and Ikris has a 5-year term and Santhera will receive a percentage of net sales, in line with previous distribution agreements. Sales are expected to begin in Q4 2025 on a named patient basis.
Dario Eklund, Chief Executive Officer of Santhera, said: “We are pleased to partner with Ikris Pharma Network in India, which is part of our wider strategy to increase global access to AGAMREE for patients with DMD. Ikris has been actively working in the area of DMD and their expertise and dedication to ensuring rare disease drugs reach patients makes them an ideal partner in the region.”
Saber mais: Esteroide milagroso Vamorolona (Agamree) pode oferecer tratamento mais seguro para DMD
Praveen Sikri, Founder & CEO of Ikris Pharma Network said: “This collaboration with Santhera aligns with our focus of addressing unmet medical needs in the rare disease community. We look forward to leveraging our distribution network to help DMD patients in India access this life-changing treatment.”
My son DMD Exon 53or 59 h Duplication h
How long and how will DMD patients get this medicine in India